• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Rafael Holdings Inc. (Amendment)

    2/28/23 11:41:29 AM ET
    $RFL
    Real Estate
    Finance
    Get the next $RFL alert in real time by email
    SC 13D/A 1 ea174329-13da1jonas_rafel.htm AMENDMENT NO. 1 TO SCHEDULE 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D/A

      

    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)

     

    Rafael Holdings, Inc.

     

    (Name of Issuer)

      

    Class B Common Stock, par value $0.01 per share

     

    (Title of Class of Securities)

      

    75062E106

     

    (CUSIP Number)

     

    Howard Jonas

    520 Broad Street

    Newark, NJ 07102

    (973) 438-1000

     

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

      

    January 18, 2019

     

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this statement because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box:  ☐

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the act (however, see the Notes).

     

     

     

     

     

     

    SCHEDULE 13D/A

     

    1

    NAME OF REPORTING PERSON 

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

     

    Howard S. Jonas

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐

    (b)  ☒

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐   
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF
    SHARES BENEFICIALLY OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

    955,027

    8

    SHARED VOTING POWER

     

    98,820

    9

    SOLE DISPOSITIVE POWER

     

    955,027

    10

    SHARED DISPOSITIVE POWER

     

    98,820

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,053,847

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐   
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    4.2%

    14

    TYPE OF REPORTING PERSON

     

    IN

     

    2

     

     

    SCHEDULE 13D/A

     

    This Amendment No. 1 to Schedule 13D (this “Amendment”) supplements and amends the information contained in the Schedule 13D originally filed with the Securities and Exchange Commission (the “Commission”) on April 12, 2018. Terms used but not defined herein shall have the meanings ascribed thereto in the Schedule 13D.

     

    Item 1. Security and Issuer

     

    This Amendment relates to shares of Class B common stock, $0.01 par value (“Class B Common Stock”) of Rafael Holdings, Inc., a Delaware corporation (the “Company” or “Rafael”).  The Company’s principal executive offices are located at 520 Broad St., Newark, NJ, 07102.

     

    Item 2. Identity and Background

     

    Mr. Howard S. Jonas. 520 Broad St., Newark, NJ 07102. Mr. Jonas is the Executive Chairman and Chairman of the Board of the Company. During the last five years, Mr. Jonas has not been convicted in a criminal proceeding. During the last five years, Mr. Jonas was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and is not subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, nor a finding of any violation with respect to such laws. Mr. Jonas is a United States citizen.

     

    Item 3. Source and Amount of Funds or Other Consideration

     

    The matters set forth in Item 4 of this Amendment are incorporated in this Item 3 by reference as if fully set forth herein.

     

    Item 4. Purpose of Transaction

     

    Item 4 is hereby amended and supplemented as follows:

     

    On January 18, 2019, Mr. Jonas purchased 1,254,200 shares of Class B Common Stock from the Company at a price of $6.89 per share.

     

    On June 25, 2019, Mr. Jonas transferred 1,265,804 shares of Class B Common Stock from his direct holdings to the Howard S. Jonas 2017 Annuity Trust.

     

    On August 7, 2019, the Howard S. Jonas 2017 Annuity Trust acquired 1,849,749 shares of Class B Common Stock from the Company at a price of $8.47 per share upon conversion of a $15 million promissory note made by the Company.

     

    On April 6, 2020, the Howard S. Jonas 2017 Annuity Trust transferred 787,163 shares of Class A Common Stock and 4,306,738 shares of Class B Common Stock in substantially equal amounts to eight trusts for the benefit of eight of Mr. Jonas’ children. Mr. Jonas no longer has, or reports, beneficial ownership of the shares held in these trusts, as there is an independent trustee for each trust.

     

    3

     

     

    SCHEDULE 13D/A

     

    Item 5. Interest in Securities of the Issuer

     

    Items 5(a) and (b) are hereby amended by deleting them in their entirety and substituting the following therefor:

     

    As of the date hereof, Mr. Jonas beneficially owns 1,053,847 shares of the Company’s Class B Common Stock consisting of: (i) 66,490 shares of Class B Common Stock, (ii) 385,640 restricted shares of Class B Common Stock that are scheduled to vest as follows: 33,245 on March 13, 2023, 192,820 shares on June 13, 2023 and 159,575 shares on June 13, 2024, (iii) 98,820 shares of Class B Common Stock owned by The Jonas Foundation; (iv) 778 shares held in a custodial account for the benefit of one of Mr. Jonas’s children (of which Mr. Jonas is the custodian); (v) 2,119 shares held by Mr. Jonas in his IDT Corporation 401(k) plan account as of October 31, 2022; and (vi) currently exercisable options to purchase 500,000 shares. 

     

    Mr. Jonas’ beneficial ownership represents approximately 4.2% of the issued and outstanding shares and 1.2% of the combined voting power of the Company’s outstanding capital stock (assuming exercise of the options to purchase 500,000 shares of Class B common stock held by Mr. Jonas), based on 787,163 shares of Class A Common Stock and 23,685,491 shares of Class B Common Stock (excluding treasury shares) issued and outstanding as of December 9, 2022, the date of the most recently filed Form 10-Q.

     

    Mr. Jonas, his wife Deborah Jonas, and the Jonas Foundation each have the shared power to cast or to direct the casting of one-tenth of a vote per share on 98,820 shares of Class B Common Stock held by the Jonas Foundation and have the shared power to dispose or to direct the disposition of such shares. Mr. Jonas is a co-trustee of the Jonas Foundation.

     

    As used herein, the term “beneficially owns” shall be construed as defined by Rule 13d-3 promulgated under the Securities Exchange Act of 1934.

     

    (c) Except as described herein, no transactions in the Class B Common Stock were effectuated by the Reporting Person during the 60 days prior to the date of this Amendment.

     

    (d) Not applicable.

     

    (e) Mr. Jonas ceased to be the beneficial owner of more than 5% of the shares of Class B Common Stock on April 6, 2020.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer  

     

    Not applicable.

     

    Item 7. Material to be Filed as Exhibits

     

    Not applicable.

     

    4

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 28, 2023

     

    /s/ Howard S. Jonas

     
    Howard S. Jonas  

     

     

    5

     

     

    Get the next $RFL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RFL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RFL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data

      Phase 3 TransportNPC study to continue based on the independent DMC review of safety and efficacy data at prespecified 48-week interim analysis Data on the investigational candidate Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin), indicates that it is well-tolerated and has a safety profile consistent with the previously completed phase 1 and 2 studies and ongoing phase 1 open-label extension study NEWARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) announced today that its subsidiary Cyclo Therapeutics' 96-week pivotal phase 3 TransportNPC study evaluating intravenous (IV) Trappsol® Cyclo™ for the potential treatment of Niemann-Pick Disease Type

      6/18/25 7:00:00 AM ET
      $RFL
      Real Estate
      Finance
    • Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

      NEWARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL), today reported its financial results for the third quarter and first nine months of fiscal year 2025 ended April 30, 2025. "We are pleased to have completed our merger with Cyclo Therapeutics and look forward to reporting the topline data from the 48-week interim analysis of the pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 anticipated later this month," said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings. Mr. Jonas added, "We have enhanced our financial position with the cl

      6/11/25 7:00:00 AM ET
      $RFL
      Real Estate
      Finance
    • Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

      NEWARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) announced today the final results and closing of its $25.0 million rights offering (the "Rights Offering"). The subscription period of the Rights Offering expired at 5:00 P.M. Eastern Time, on May 29, 2025. The Rights Offering resulted in subscriptions for 3,130,480 shares of Class B common stock at an exercise price of $1.28 per share for aggregate gross proceeds of $4,007,014.40.The subscriptions do not reflect subscription rights held by Howard Jonas, Chief Executive Officer, President and Executive Chairman of the Company and Chairman of the Board of Directors of the Company, and his affiliates w

      6/4/25 4:01:00 PM ET
      $RFL
      Real Estate
      Finance

    $RFL
    SEC Filings

    See more
    • Rafael Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Rafael Holdings, Inc. (0001713863) (Filer)

      6/18/25 7:13:55 AM ET
      $RFL
      Real Estate
      Finance
    • SEC Form 10-Q filed by Rafael Holdings Inc.

      10-Q - Rafael Holdings, Inc. (0001713863) (Filer)

      6/11/25 7:53:42 AM ET
      $RFL
      Real Estate
      Finance
    • Rafael Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Rafael Holdings, Inc. (0001713863) (Filer)

      6/11/25 7:19:07 AM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Exec Chairman, CEO & President Jonas Howard S bought $16,742,985 worth of Class B Common Stock (13,080,457 units at $1.28) (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      6/9/25 5:19:19 PM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Exec Chairman, CEO & President Jonas Howard S was granted 118,596 units of Class B Common Stock, increasing direct ownership by 75% to 277,612 units (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      6/17/25 2:22:37 PM ET
      $RFL
      Real Estate
      Finance
    • Exec Chairman, CEO & President Jonas Howard S bought $16,742,985 worth of Class B Common Stock (13,080,457 units at $1.28) (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      6/9/25 5:19:19 PM ET
      $RFL
      Real Estate
      Finance
    • Chief Financial Officer Polinsky David exercised 76,882 in-the-money units of Class B Common Stock at a strike of $1.28, increasing direct ownership by 40% to 270,422 units (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      5/30/25 1:56:44 PM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Rafael Holdings Inc.

      SC 13D/A - Rafael Holdings, Inc. (0001713863) (Subject)

      9/30/24 5:40:03 PM ET
      $RFL
      Real Estate
      Finance
    • Amendment: SEC Form SC 13D/A filed by Rafael Holdings Inc.

      SC 13D/A - Rafael Holdings, Inc. (0001713863) (Subject)

      6/18/24 6:12:11 PM ET
      $RFL
      Real Estate
      Finance
    • SEC Form SC 13D/A filed by Rafael Holdings Inc. (Amendment)

      SC 13D/A - Rafael Holdings, Inc. (0001713863) (Filed by)

      10/24/23 4:43:18 PM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Leadership Updates

    Live Leadership Updates

    See more
    • Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

      CRANBURY, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. ("Cornerstone" or the "Company"), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the appointment of Jason Locasale, Ph.D., as a member of the Company's Scientific Advisory Board. Dr. Locasale is a highly respected scholar and brings to Cornerstone deep expertise in cancer metabolism, metabolomics, nutrition and the metabolic interface of epigenetics. "Dr. Locasale is an internationally recognized leader in the use of metabolomics approaches to study cancer biology and metabolism," said Sanjeev Luther, President & CEO at Cornerstone Pharmaceutical

      7/6/22 8:00:00 AM ET
      $RFL
      Real Estate
      Finance